Divis Laboratories Limited has uploaded the audio recording of its earnings conference call for the quarter ended June 30, 2026, to its official website. The call took place on August 01, 2026, at 14:00 Hrs (IST), providing investors and analysts with direct access to management’s commentary on the company’s financial performance for Q1 FY27. This disclosure ensures transparency and allows stakeholders who could not attend the live session to review the detailed discussion on operational and financial metrics.

The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Divis Laboratories informed both the National Stock Exchange of India Limited and BSE Limited about the availability of the recording. This follows an earlier intimation letter dated July 24, 2026, which notified investors about the scheduled earnings call. The regulatory filing ensures that all market participants have equal access to material information regarding the company’s quarterly results.

Accessing the Earnings Call Recording

Investors can access the audio file through the Investors Relations section of the Divis Laboratories Limited website. The recording is hosted as a webm file, ensuring compatibility with most modern browsers and devices. The specific weblink provided in the exchange filing directs users to the Q1 FY27 earnings call audio, facilitating easy retrieval without navigating through multiple pages. This digital accessibility aligns with modern corporate governance practices aimed at enhancing investor engagement.

Regulatory Compliance and Filing Details

The communication was signed by M. Satish Choudhury, Company Secretary & Compliance Officer of Divis Laboratories Limited. The digital signature confirms the authenticity of the disclosure, dated August 01, 2026, at 15:35:30 +05'30'. The filing explicitly references the trading symbol DIVISLAB and scrip code 532488, ensuring clear identification of the entity involved. By adhering to SEBI’s listing obligations, the company maintains its commitment to timely and accurate disclosure of material events.

Divi's Laboratories Limited reported a consolidated profit after tax (PAT) of ₹902 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 65% year-on-year increase from ₹545 crore in the corresponding period of the previous year. The Hyderabad-based pharmaceutical manufacturer also saw its revenue from operations jump 28% to ₹3,080 crore, up from ₹2,410 crore in Q1FY26. This performance underscores the company’s robust operational momentum despite a forex headwind that reversed from a gain in the prior year to a loss in the current period.

The Board of Directors approved the unaudited financial results at its meeting held on August 01, 2026. In addition to the financial outcomes, the Board appointed Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 01, 2026. The results were reviewed by the statutory auditors, Price Waterhouse Chartered Accountants LLP, which issued an unmodified limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

On a consolidated basis, Divi’s Laboratories generated total income of ₹3,144 crore in Q1FY27, compared to ₹2,529 crore in Q1FY26. Profit before tax (PBT) rose sharply to ₹1,180 crore from ₹733 crore in the prior-year quarter. Standalone PAT grew 60% to ₹891 crore from ₹557 crore, while standalone revenue reached ₹2,974 crore, up from ₹2,357 crore.

Earnings per share (EPS) on a consolidated basis stood at ₹33.95, compared to ₹20.49 in the same quarter last year. On a standalone basis, EPS was ₹33.55, up from ₹20.95.

Operational Insights

A notable variance in the current quarter was the impact of foreign exchange movements. Divi’s Laboratories recorded a forex loss of ₹7 crore in Q1FY27, contrasting with a forex gain of ₹39 crore in Q1FY26. Despite this reversal, the company maintained strong margin expansion, driven by higher volume realization and operational efficiencies. The tax expense for the quarter was ₹278 crore on a consolidated basis, including deferred tax benefits.

Management Appointments

The Board approved the appointment of two key executives to the Senior Management Personnel category:

• B. Vara Prasad: General Manager (Engineering Purchase) with over 31 years of experience in supply chain and procurement. He joins the senior management team effective August 01, 2026.
• J. Srinivasa Rao: General Manager (Raw Materials Purchase) with over 30 years of experience in pharmaceutical procurement. He also assumes his new role effective August 01, 2026.

These appointments aim to strengthen the company’s procurement and supply chain leadership as it scales its manufacturing capabilities.